Comparison
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738 vs 3m Syndrome 1 C2678312
Clinical comparison between 3 Hydroxyisobutyryl Coa Hydrolase Deficiency and 3M Syndrome 1 for differential diagnosis and treatment planning.
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
A metabolic disorder affecting the breakdown of amino acids. It may cause neurological problems, developmental delay, and metabolic disturbances. Treatment focuses on dietary management and supportive interventions.
3m Syndrome 1 C2678312
A genetic disorder causing severe short stature with distinctive facial features and skeletal abnormalities. Management involves monitoring growth and addressing orthopedic or other associated concerns.
6 comparison axes
Onset
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
0-3
3m Syndrome 1 C2678312
0-0
Onset patterns differ
Severity
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
severe
3m Syndrome 1 C2678312
moderate
Different severity levels
Chronic
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
Chronic
3m Syndrome 1 C2678312
Chronic
Differing course
Communicable
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
No
3m Syndrome 1 C2678312
No
Different transmission
Body System
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
metabolic
3m Syndrome 1 C2678312
musculoskeletal
Same/different system
Category
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
metabolic
3m Syndrome 1 C2678312
genetic
Different category
Bottom line
3-hydroxyisobutyryl-coa-hydrolase-deficiency-C0342738 and 3m-syndrome-1-C2678312 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738 | 3m Syndrome 1 C2678312 | Discriminating power |
|---|---|---|---|
| Growth pattern | Short stature is not the defining feature in the supplied description. | Severe short stature is characteristic and often evident from birth. | High |
| Neurologic course | Neurologic problems and developmental delay may occur. | Neurologic disease is not the main described feature. | Moderate |
| Facial and skeletal appearance | No specific skeletal syndrome is established by this source. | Distinctive facial features and skeletal abnormalities are typical. | High |
When to favor each condition
Choose 3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738 when
Unexplained metabolic or neurologic findings in infancy or early childhood
The source describes impaired amino-acid breakdown with possible metabolic disturbance.
Moderate
Clinical picture suggests an inborn error rather than a primary growth syndrome
Its metabolic category and dietary or supportive management fit the left condition.
Moderate
An abnormal metabolic result needs disease-level interpretation
An abnormal test is not itself a diagnosis and requires clinician review.
High
Choose 3m Syndrome 1 C2678312 when
Congenital severe short stature with characteristic facial features
This matches the described musculoskeletal genetic phenotype.
High
Orthopedic or skeletal concerns dominate care
Management emphasizes growth monitoring and associated skeletal issues.
Moderate
Evaluation points to a noncommunicable congenital growth disorder
The source classifies it as genetic and present from birth.
Moderate
How key tests differ
| Test | 3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738 | 3m Syndrome 1 C2678312 | Interpretation |
|---|---|---|---|
| Metabolic studies | May suggest disturbed amino-acid metabolism; no cutoff is supplied. | Not expected to establish this growth syndrome. | Abnormal metabolites need specialist confirmation and are not diagnostic alone. |
| Genetic testing | May support HIBCH-related deficiency when correlated clinically. | May identify a 3M syndrome-related variant, often involving CUL7 in type 1. | Variant significance should be interpreted by a genetics clinician. |
| Growth and skeletal assessment | No specific skeletal pattern is established here. | May document short stature and skeletal abnormalities. | Phenotype supports suspicion but does not replace genetic diagnosis. |
Prognosis comparison
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
- Outcome
- Described as severe and chronic, but individual outcome is not established here.
- Factors
- Neurologic involvement and metabolic stability may matter; exact predictors are unavailable.
3m Syndrome 1 C2678312
- Outcome
- Described as a moderate chronic condition centered on growth and skeleton.
- Factors
- Degree of short stature and orthopedic needs may influence the course.
Time frame: Lifelong; right is present at birth, while left may emerge in early childhood.
Prognosis is individualized. Mortality and prevalence are not stated.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Developmental delay or neurologic problems may occur. Not described as the defining complication. Severity varies, and precise rates are not established here. |
| Metabolic disturbance | Metabolic disturbances may occur. Not described as a primary metabolic disorder. Triggers and laboratory thresholds are not supplied. |
| Orthopedic problems | Not a primary musculoskeletal syndrome in this source. Skeletal abnormalities may require monitoring or orthopedic care. Exact complication frequency is not provided. |
Patient education highlights
- HighDistinct conditions
These are unrelated rare disorders: one metabolic and one a congenital growth syndrome.
- HighTests versus diagnosis
An abnormal laboratory result requires clinician review before a disease label is applied.
- MediumCare focus
Left care is dietary and supportive; right care monitors growth and orthopedic concerns. No doses are implied.